Neurocardiogenic syncope is not classified as an autoimmune disease. It is a reflex-mediated condition caused by an exaggerated response of the autonomic nervous system, the network of nerves that controls involuntary functions like heart rate and blood pressure. That said, research into related conditions like POTS (postural orthostatic tachycardia syndrome) has uncovered autoimmune markers that overlap with some autonomic disorders, which is likely why this question comes up.
What Neurocardiogenic Syncope Actually Is
Neurocardiogenic syncope, also called vasovagal syncope, is the most common cause of fainting in both children and adults, accounting for 50 to 66% of unexplained syncope cases. It has a mean prevalence of about 22% in the general population. Medically, syncope is considered a symptom rather than a disease in its own right.
The basic mechanism involves a neural reflex that goes haywire. When you stand for a long time, experience strong emotion, or encounter certain other triggers, specialized nerve fibers in the heart (called C fibers) become overstimulated. This sets off a chain reaction: blood vessels dilate, the vagus nerve slows your heart rate, blood pressure drops, and your brain temporarily loses enough blood flow to cause you to pass out. The episode is usually self-limiting, meaning it resolves on its own once you’re horizontal and blood flow returns to normal.
The key point is that the underlying problem is a misfiring reflex, not the immune system attacking the body’s own tissues. This places neurocardiogenic syncope firmly in the category of autonomic dysfunction rather than autoimmune disease.
Where the Autoimmune Question Comes From
The confusion likely stems from research into POTS, a related autonomic condition that shares some features with neurocardiogenic syncope. In recent years, investigators have found several types of autoantibodies in patients with POTS, particularly antibodies that target G protein-coupled receptors (GPCRs). These receptors sit on cell surfaces and help regulate heart rate, blood vessel tone, and other cardiovascular functions. When autoantibodies bind to them, they can either ramp up or dampen the receptor’s activity, potentially disrupting normal cardiovascular control.
Specific findings in POTS patients include autoantibodies that activate certain adrenaline receptors and acetylcholine receptors to a significantly higher degree than in healthy controls. One research group demonstrated that antibodies against one type of adrenaline receptor boosted its activity, while antibodies against another type suppressed it. Antibodies against angiotensin receptors, which help regulate blood pressure, have also been found. These discoveries have led some researchers to propose an autoimmune origin for at least a subset of POTS cases.
Importantly, though, when one research group directly compared POTS patients and people with recurrent vasovagal syncope, the autoantibody levels against adrenaline receptors were significantly higher in the POTS group than in the vasovagal syncope group or healthy controls. In other words, the autoimmune signal that shows up in POTS does not appear to carry over to neurocardiogenic syncope in the same way.
Autoimmune Autonomic Ganglionopathy: A Different Condition
There is a genuinely autoimmune condition that affects the autonomic nervous system: autoimmune autonomic ganglionopathy (AAG). It involves antibodies that attack receptors in the autonomic ganglia, the relay stations where nerve signals are passed along. About 50% of patients with acute or subacute AAG have detectable antibodies against these receptors, and higher antibody levels correlate with more severe, widespread autonomic failure.
AAG looks quite different from neurocardiogenic syncope. People with AAG typically develop orthostatic hypotension (a sustained drop in blood pressure upon standing, present in about 75% of cases), along with gastrointestinal problems (74%), bladder dysfunction (56%), dry eyes and mouth (45%), and sometimes pupil abnormalities. Around 80% also experience symptoms beyond the autonomic system, including numbness, cognitive dysfunction, and psychiatric changes. This widespread pattern of dysfunction is a far cry from the episodic fainting of neurocardiogenic syncope.
If your doctor suspects an autoimmune cause for your autonomic symptoms, testing for ganglionic receptor antibodies can help distinguish AAG from other forms of dysautonomia.
Inflammatory Markers in Vasovagal Syncope
While neurocardiogenic syncope is not autoimmune, that does not mean the immune system plays zero role. Research published in Frontiers in Cardiovascular Medicine found that children with vasovagal syncope had a distinct pattern of growth-related signaling proteins in their blood compared to healthy children. Levels of hepatocyte growth factor and certain insulin-like growth factor binding proteins were elevated, while epidermal growth factor was lower. These molecules play roles in tissue repair, inflammation, and blood vessel function.
This does not make vasovagal syncope an inflammatory or autoimmune disease. But it does suggest the condition involves more biological complexity than a simple nerve reflex misfiring, and it opens the door to better understanding of why some people are prone to recurrent episodes while others are not.
Immunotherapy Is Not Standard Treatment
Because neurocardiogenic syncope is not autoimmune, immune-based treatments like immunoglobulin infusions, plasma exchange, or corticosteroids are not part of its standard management. These therapies have been explored in severe, treatment-resistant POTS, where case reports and small case series suggest they may help some patients. But even in POTS, large controlled trials have not yet been completed, and these approaches remain experimental.
For neurocardiogenic syncope, the mainstay of management focuses on avoiding known triggers, staying well hydrated, increasing salt intake, using physical counterpressure maneuvers (like tensing your leg muscles when you feel faint), and in some cases, medications that support blood pressure or heart rate. The treatment approach reflects the condition’s nature as a reflex problem rather than an immune system attack.
Why the Distinction Matters
Knowing that neurocardiogenic syncope is a reflex disorder and not an autoimmune disease changes what testing makes sense, what treatments are appropriate, and what you should expect over time. Autoimmune conditions like AAG tend to be progressive and require immune-suppressing therapy. Neurocardiogenic syncope, while sometimes frustrating and recurrent, is generally not dangerous and often improves with lifestyle modifications.
If you have recurrent fainting along with widespread symptoms like chronic gastrointestinal problems, bladder issues, or dry eyes and mouth, it may be worth asking about autoimmune autonomic conditions specifically. But isolated episodes of fainting triggered by standing, heat, or emotional stress point toward the far more common, non-autoimmune explanation.